Jameson GS, Borazanci E, Babiker HM, et al. - In this single-arm, open-label, phase 1b/2 clinical trial in which 25 individuals with formerly untreated metastatic pancreatic ductal adenocarcinoma (PDA) were recruited, researchers ascertained response rate after treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for individuals with metastatic PDA. In this small study, this triple-drug regimen explicated principal clinical activity. Among individuals with advanced PDA treated with this combination, however, the primary endpoint was not attained, the high overall response rate, disease control rate, and median survival time were strengthening. Moreover, in individuals with PDA in the neoadjuvant setting and in patients with advanced biliary cancers, this regimen is being reviewed.